Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
11/11/2022* -- Results Q3 2022 -- 0.73 --
07/29/2022 -- Results Q2 2022 0.86 1.04 -17.32%
04/29/2022 -- Results Q1 2022 0.95 1.15 -17.65%
02/10/2022 -- Results Q4 2021 0.84 0.99 -15.58%
11/12/2021 -- Results Q3 2021 0.54 0.91 -40.88%
07/29/2021 -- Results Q2 2021 0.45 0.69 -34.38%
04/30/2021 -- Results Q1 2021 0.82 0.96 -15.29%
02/11/2021 -- Results Q4 2020 -- 0.76 --
*Estimated Date/Time

Earnings

Next Report Date 11/11/2022 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 07/29/2022
Beat/Miss Upgrade
Return Since -19.37%
Last FQE 06/30/2022
Next FQE 09/30/2022

Profile

Edit
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
URL https://www.astrazeneca.com
Investor Relations URL https://www.astrazeneca.com/investor-relations.html
HQ State/Province N/A
Sector Healthcare
Industry Drug Manufacturers - General
Equity Style Large Cap/Growth
Next Earnings Release Nov. 11, 2022 (est.)
Last Earnings Release Jul. 29, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date Aug. 11, 2022

Dividends

Dividend Per Share (TTM) 1.435
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 1.911
Yield to Sector 1.474
Yield to Industry 0.7372
Last Dividend Amt. 0.465
Dividend Frequency Semi-Annually
Last Ex-Dividend Date Aug. 11, 2022
Yield (TTM) 2.72%
Forward Yield 2.73%
Payout Ratio -347.8%
Cash Payout Ratio 81.72%
Consistent Payer (5Y) Yes
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
0.53%
-15.87%
33.20%
13.79%
35.65%
3.20%
19.72%
-6.77%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-22.42%
0.86%
3.28%
-1.81%
15.13%
30.64%
-16.73%
28.38%
-33.69%
--
--
--
--
28.09%
434.1%
143.1%
-52.87%
--
--
--
--
--
140.6%
216.2%
-49.82%
-3.45%
-1.15%
9.94%
5.95%
20.53%
0.31%
7.02%
-22.76%
As of September 26, 2022.

Profile

Edit
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
URL https://www.astrazeneca.com
Investor Relations URL https://www.astrazeneca.com/investor-relations.html
HQ State/Province N/A
Sector Healthcare
Industry Drug Manufacturers - General
Equity Style Large Cap/Growth
Next Earnings Release Nov. 11, 2022 (est.)
Last Earnings Release Jul. 29, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date Aug. 11, 2022

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
THW 25.04M USD 5.06%
HHL.TO 54.88M USD 5.04%
PPH 26.74M USD 4.77%
DXG.TO 37.64M USD 4.56%
VPCCX 373.75M USD 3.62%
THISX 523.86M USD 3.38%
VPMCX 1.711B USD 2.86%
PAVLX 803.52M USD 2.59%
HQH 23.49M USD 2.31%
NUGO 42.88M USD 1.66%
CWMFX 1.481B USD 1.02%
VWELX 1.049B USD 1.00%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter AZN Tweets